NCT04169906View on ClinicalTrials.gov

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 6, 2016

Primary Completion Date

October 8, 2016

Study Completion Date

October 8, 2016

Conditions
Healthy Volunteer
Interventions
DRUG

Placebo

Participants will receive placebo once daily for 7 consective days

DRUG

TS-142, 10 mg

Participants will receive 10 mg of TS-142 once daily for 7 consective days

DRUG

TS-142, 20 mg

Participants will receive 20 mg of TS-142 once daily for 7 consective days

DRUG

TS-142, 30 mg

Participants will receive 30 mg of TS-142 once daily for 7 consective days

Trial Locations (1)

Unknown

The medical facility selected by Taisho Pharmaceutical Co., Ltd, Fukuoka

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT04169906 - A Phase I Study of TS-142 in Healthy Participants (Repeated Doses) | Biotech Hunter | Biotech Hunter